WASHINGTON — The White House at long last published a plan to stem drug shortages, and it involves basing Medicare pay to hospitals on whether hospitals adopt business practices that avoid shortages.
The White House formed a task force at the beginning of 2023 to deal with the issue of persistent drug shortages, including cancer drugs. As of late last summer, lawmakers working on drug shortage legislation hadn’t spoken to the task force and didn’t know who was in charge of it.
There are many proposals in Congress for fixing the problem, but they don’t form a cohesive whole. The various approaches include improving drug manufacturing, boosting domestic manufacturing, giving hospitals the incentive to buy from generic drugmakers that maintain resilient supply chains, and helping generic drugmakers charge higher prices.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect